RESTOR Trial
EARLY_PHASE1
194
about 3 years
65–90
1 site in TX
About this study
This trial is testing whether Everolimus or Rapamycin can safely slow down aging in older adults. The goal is to find a safe dose and timing for these drugs that can inhibit mTOR, a process related to aging, at levels similar to those seen in younger people. This research will also investigate how the best dose might differ between men and women.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Everolimus
- 3.Take Rapamycin
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
mTOR inhibitor, sirolimus
oral (Oral Tablet)
Primary: PD measure of inhibition of mTOR activity in blood cells - p-rpS6, Pharmacokinetics (PK) of mTOR inhibitor in blood
Secondary: PD measure of inhibition of mTOR activity in PBMCs Akt, PD measure of inhibition of mTOR activity in PBMCs, S6-kinase, PD measure of inhibition of mTOR activity in adipose (fat) cells Akt (Aim 2 only), PD measure of inhibition of mTOR activity in adipose cells, rpS6 (Aim 2 only), PD measure of inhibition of mTOR activity in fat cells (Aim 2 only) - pS6K, PD measure of inhibition of mTOR activity in muscle (Aim 2 only) - pS6K, PD measure of inhibition of mTOR activity in muscle Akt (Aim 2 only), PD measure of inhibition of mTOR activity in muscle rpS6 (Aim 2 only)